NCT01717768View on ClinicalTrials.gov

Oral Testosterone for the Treatment of Hypogonadism

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

December 31, 2014

Conditions
Hypogonadism
Interventions
DRUG

TSX-002

TSX-002 are capsules with testosterone as the active ingredient.

Trial Locations (1)

90048

Urology Group of Southern California, Los Angeles

All Listed Sponsors
lead

TesoRx Pharma, LLC

INDUSTRY

NCT01717768 - Oral Testosterone for the Treatment of Hypogonadism | Biotech Hunter | Biotech Hunter